conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the
most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug
conjugates manufacturing is currently outsourced. There are limited number of contract
manufacturers that have high-end manufacturing equipment for development of cytotoxins.
Antibody drug conjugates market is still in its infancy, with two approved ADCs to propel the
market to two digit billion dollar mark by 2020
The global antibody drug conjugates market is segmented on the basis of drug and geography. On
the basis of drug, the market is divided into Adcetris and Kadcyla.
Major pharmaceutical company opt for contract manufacturer for development and
manufacture of antibody drug conjugates
Regional segmentation of the antibody drug conjugates market by Coherent Market Insights
comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Europe
accounts for the largest share in the global market mainly due to presence of many contract
manufacturing companies with advanced manufacturing equipment. Lonza is one of the top contract
manufacturing companies in Europe, which has operations across France and Germany, with its
headquarters in Switzerland. One of the facilities operated by the company is a deck to chemical
manufacturing capabilities and develop peptides, small molecule active pharmaceutical ingredients,
highly potent active pharmaceutical ingredients, cytotoxics agents, antibody drug conjugates, and
microbial products. The company also offer proficiency in chemical, pharmaceutical, agrochemical
and food industries by providing clients with yields such as high-class active substances, organic
chemicals and intermediates.
Large number of clinical trial molecules in pipeline to boost growth of antibody drug
conjugates market
Key players operating the antibody drug conjugates market include Hoffmann-La Roche Ltd,
Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics,
Synthon, and Progenics Pharmaceuticals. Major companies in the antibody drug conjugates industry
are constantly working on research and development, as the market is largely untapped and offer
highly lucrative growth opportunities. For instance, there are only two antibody drug conjugates
available worldwide that are used to treat cancer, and there are over 40 molecules under clinical
trials. Considering the alarmingly high incidence rate of cancer across the globe, the antibody
conjugates market is expected to ride on a wave of positive growth in the foreseeable future.
Request For Customization @ https://www.coherentmarketinsights.com/insight/request-
customization/181
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,